- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Marvel Biosciences Corp: Marvel Biosciences picks CMAX for MB-204 phase 1 trial | 1 | Stockwatch | ||
| Mo | Marvel Biosciences Corp.: Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site | 1 | GlobeNewswire (USA) | ||
| 09.10. | Marvel Biosciences Corp: Marvel Biosciences 10,654,298-share private placement | 1 | Stockwatch | ||
| 08.10. | Marvel Biosciences Corp.: Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model | 173 | GlobeNewswire (Europe) | CALGARY, Alberta, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL - OTCQB: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or... ► Artikel lesen | |
| 06.10. | Marvel Biosciences Corp: Marvel Biosciences signs LOI with Novatech for trial | 3 | Stockwatch | ||
| 06.10. | Marvel Biosciences Corp.: Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update | 188 | GlobeNewswire (Europe) | CALGARY, Alberta, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL - OTCQB: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or... ► Artikel lesen | |
| MARVEL BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 30.09. | Marvel Biosciences closes private placement for C$1.6M | 3 | Investing.com | ||
| 30.09. | Marvel Biosciences Corp.: Marvel Biosciences Announces Closing of Private Placement For Up To $3.0 Million | 619 | Newsfile | Calgary, Alberta--(Newsfile Corp. - September 29, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ("Marvel" or the "Company") announced today that, further to its July 16, 2026, August... ► Artikel lesen | |
| 17.09. | Marvel Biosciences announces non-brokered private placement for up to $3M | 1 | Seeking Alpha | ||
| 17.09. | Marvel Biosciences plant Privatplatzierung von bis zu 3 Mio. C$ | 1 | Investing.com Deutsch | ||
| 17.09. | Marvel Biosciences plans private placement of up to C$3M | 1 | Investing.com | ||
| 17.09. | Marvel Biosciences Corp.: Marvel Biosciences Provides Update on Private Placement for up to $3.0 Million | 605 | Newsfile | Calgary, Alberta--(Newsfile Corp. - September 17, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ("Marvel" or the "Company") announced today that, further to its July 16, 2026, August... ► Artikel lesen | |
| 10.09. | Marvel Biosciences Corp: Marvel Biosciences extends placement to Sept. 14 | 1 | Stockwatch | ||
| 09.09. | Marvel Biosciences gets approval to extend private placement deadline | 1 | Investing.com | ||
| 09.09. | Marvel Biosciences Corp.: Marvel Biosciences Announces Extension to Closing Date of Private Placement | 489 | Newsfile | Calgary, Alberta--(Newsfile Corp. - September 9, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ("Marvel" or the "Company") announces that it has received approval from the TSX Venture... ► Artikel lesen | |
| 20.08. | Marvel Biosciences Corp: Marvel Biosciences expands financing to Quebec | 2 | Stockwatch | ||
| 19.08. | Marvel Biosciences Corp.: Marvel Biosciences Expands Private Placement to Quebec | 531 | Newsfile | Calgary, Alberta--(Newsfile Corp. - August 19, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ("Marvel" or the "Company") announces that it is expanding its previously announced private... ► Artikel lesen | |
| 05.08. | Marvel Biosciences Corp: Marvel Biosciences talks MB-204 preclinical data | 1 | Stockwatch | ||
| 05.08. | Marvel Biosciences Corp.: Marvel Biosciences Reports Positive Preclinical Data Demonstrating MB-204 Reverses Behavioural and Cognitive Deficits in a Mouse Model of Fragile X | 205 | GlobeNewswire (Europe) | CALGARY, Alberta, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL - OTC: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel")... ► Artikel lesen | |
| 17.07. | Marvel Biosciences Corp: Marvel Biosciences arranges minimum $1.5M placement | 1 | Stockwatch |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 42,830 | +3,84 % | Finanzinvestor EQT will Qiagen für über 9 Milliarden Euro kaufen - Agentur | DJ Finanzinvestor EQT will Qiagen für über 9 Milliarden Euro kaufen - Agentur
DOW JONES--Der Finanzinvestor EQT will einem Agenturbericht zufolge den Diagnostikspezialisten Qiagen übernehmen. Wie... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 83,17 | 0,00 % | AstraZeneca, Cardiol Therapeutics, Kiniksa - Neue Hoffnung für Herzpatienten | Herz-Kreislauf-Erkrankungen gehören weltweit zu den größten medizinischen Herausforderungen. Während etablierte Pharmakonzerne Milliarden in neue Wirkstoffe und Künstliche Intelligenz investieren, entwickeln... ► Artikel lesen | |
| RAPPORT THERAPEUTICS | 29,310 | -0,20 % | Guggenheim raises Rapport Therapeutics price target to $70 on trial data | ||
| PRAXIS PRECISION MEDICINES | 264,61 | +0,05 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| TANGO THERAPEUTICS | 25,250 | 0,00 % | Tango Therapeutics (TNGX) Has Striking Pancreatic Cancer Data. How Much Is Priced In? | ||
| DISC MEDICINE | 79,45 | -0,04 % | Disc Medicine prices $450 million stock offering at $75/share | ||
| ARCUTIS BIOTHERAPEUTICS | 32,810 | 0,00 % | Arcutis BioTherapeutics advances 11% to new 52-week high | ||
| SUMMIT THERAPEUTICS | 16,095 | +0,03 % | Summit Therapeutics Secures $2B Strategic Investment From AstraZeneca | LONDON (dpa-AFX) - Summit Therapeutics Inc. (SMMT) on Monday announced the closing of AstraZeneca's (AZN) $2 billion strategic equity investment, which will support accelerated development of... ► Artikel lesen | |
| NURIX THERAPEUTICS | 26,130 | +0,11 % | H.C. Wainwright raises Nurix stock price target on strong revenue | ||
| MAZE THERAPEUTICS | 32,450 | 0,00 % | Canaccord stuft Maze Therapeutics mit "Buy" ein - Nierentherapien bieten hohes Kurspotenzial | ||
| ABSCI | 9,070 | 0,00 % | Absci Corporation: Absci Announces Preliminary Details for Phase 2 STORYLINE Trial of AI-Designed Antibody ABS-201 for Endometriosis | Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial... ► Artikel lesen | |
| VERADERMICS | 127,66 | +0,34 % | Veradermics' hot streak continues with another phase 3 win in hair loss | ||
| RECURSION PHARMACEUTICALS | 3,665 | +0,14 % | Cathie Wood's weekly recap: adds to CoreWeave, Meta, Recursion; cuts Personalis, Toast | ||
| EDGEWISE THERAPEUTICS | 39,730 | -0,05 % | William Blair initiates Edgewise Therapeutics stock with outperform rating | ||
| IMMUNOME | 17,920 | 0,00 % | William Blair initiates Immunome stock coverage with outperform rating |
Das Unternehmen MARVEL BIOSCIENCES CORP kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MARVEL BIOSCIENCES CORP finden Sie auf Wallstreet Online.